Benefits
Easier breathing and airway support
AlvioLife® reduces bronchial airway inflammation through Boswellia's AKBA (acetyl-11-keto-β-boswellic acid) inhibition of 5-lipoxygenase — the enzyme producing leukotrienes that trigger bronchoconstriction and airway inflammation. This mechanism is the same target as pharmaceutical leukotriene inhibitors (montelukast) but through a botanical route, supporting freer, less restricted breathing.
Enhanced physical performance and VO2
By improving respiratory efficiency and reducing airway resistance, AlvioLife® allows athletes to draw more oxygen per breath — translating to improved VO2 utilization, greater endurance capacity, and better performance during sustained aerobic exercise. Clinical studies show improvements in respiratory function markers and exercise performance.
Immune and respiratory resilience
Spilanthes acmella provides immunostimulatory alkylamides (spilanthol) that activate macrophages and natural killer cells — enhancing upper respiratory immune defense. The combination of anti-inflammatory Boswellia and immunostimulatory Spilanthes creates a dual protective and active immune profile for respiratory health.
Mechanism of action
5-LOX inhibition and leukotriene reduction
AKBA from Boswellia serrata selectively inhibits 5-lipoxygenase (5-LOX) — the enzyme responsible for converting arachidonic acid to pro-inflammatory leukotrienes (LTB4, LTC4, LTD4). Leukotrienes are the primary mediators of bronchospasm, mucus hypersecretion, and airway inflammation in respiratory conditions. By blocking 5-LOX, AlvioLife® reduces leukotriene-driven airway constriction and inflammation without the COX inhibition side effects of NSAIDs.
Clinical trials
Manufacturer-published (PLT Health Solutions) clinical study examining AlvioLife® (a proprietary blend of Boswellia serrata and Aegle marmelos extracts) on respiratory function, breathing comfort, and exercise performance markers. Note: full details available via PLT Health Solutions; not currently indexed in PubMed.
Mild-to-moderate asthma patients. Randomized, double-blind, placebo-controlled clinical study of LI13109F (AlvioLife®, the patented Boswellia serrata + Aegle marmelos blend) on asthma symptoms and lung function.
AlvioLife® significantly alleviated symptoms of asthma vs placebo, with improvements in lung function and reductions in symptom severity. Published in PMID 29210124. A subsequent 6-week RCT in 2021 (PLT-funded, n=200mg/day in air-pollution-sensitive subjects) reported up to 16% improved FEV1, 30% improved FVC, 7% improved 6-min walk capacity, ~40% reduction in upper respiratory tract symptoms (WURSS-21), and 18% improvement in psychological well-being (PGWBI) — that pollution-sensitivity trial is in pre-publication and findings here come from PLT press releases.